Key result
In patients with cancer therapy-related cardiac dysfunction, sacubitril/valsartan improved LVEF from 33% to 42% and reduced NT-proBNP from 1552 to 776 pg/mL (P≤0.01).
Why the study?
Sacubitril/valsartan is recommended for heart failure with reduced LVEF, but evidence of its efficacy and safety in cancer therapy-related cardiac dysfunction was lacking.
Does sacubitril/valsartan improve LVEF, NT-proBNP, and functional class in patients with cancer therapy-related cardiac dysfunction?
Cohort (n=67)
Yes
Does sacubitril/valsartan improve LVEF, NT-proBNP, and functional class in patients with cancer therapy-related cardiac dysfunction?
Absolute Event Rate: 42% vs 33%
p-value: p=≤0.01
Sacubitril/valsartan is well tolerated and associated with significant improvements in LVEF, NT-proBNP, and functional class in patients with cancer therapy-related cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
May improve symptoms and LVEF in CTRCD; hypothesis-generating and requires prospective RCTs before practice change.
Martín‐Garcia et al. (2020) conducted a cohort in Cancer therapy-related cardiac dysfunction (CTRCD) (n=67). Sacubitril/valsartan vs. Baseline was evaluated on Left ventricular ejection fraction (LVEF) (p=≤0.01). In patients with cancer therapy-related cardiac dysfunction, sacubitril/valsartan improved LVEF from 33% to 42% and reduced NT-proBNP from 1552 to 776 pg/mL (P≤0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: